SS-31

SS-31 (Elamipretide / MTP-131)

In simple words

SS-31 (elamipretide) is a small peptide that enters the mitochondria, the cell's "power plants," and strengthens their inner membranes. It is studied for restoring energy production in cells, including in heart and muscle diseases.

What this molecule is

D-Arg-2'6'-dimethylTyr-Lys-Phe-NH₂ — 4 aa, D-amino acids, amidated C-terminus. ~639 Da.

Why it is studied

Mitochondrial regeneration via cardiolipin. 3 level A RCTs: ↑exercise tolerance in mitochondrial cardiomyopathy; ↑systolic function in chronic heart failure; ↓ischemic injury during reperfusion. Phase III in primary mitochondrial myopathy.

How it works

Crosses the mitochondrial membrane → binds to cardiolipin → restores cristae structure → ↑ATP synthesis +30-40% → ↓ROS. Unique feature: not a direct antioxidant, but a structural membrane stabilizer.

Doses used in studies

Studies used 5 mg a day SC for a course of 5–10 days; repeat courses twice a year.

Combined with in studies

  • Urolithin A — mitophagy + new mitochondria
  • MOTS-c — AMPK+OXPHOS
  • NAD+/NMN — sirtuin substrate

Level of evidence

Level A Human clinical trials. There are randomized controlled trials (RCTs), or the compound has been approved by a regulatory agency. The most reliable level.

Important to know

Phase III is ongoing. Requires a cold chain. An expensive peptide.

Studies in PubMed

  1. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. (Genet Med, 2021)
  2. Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. (J Card Fail, 2020)
  3. Phase 2a Clinical Trial of Mitochondrial Protection (Elamipretide) During Stent Revascularization in Patients With Atherosclerotic Renal Artery Stenosis. (Circ Cardiovasc Interv, 2017)
  4. ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation. (Ophthalmol Sci, 2025)
  5. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. (Neurology, 2023)

Research peptides are laboratory reagents (Research Use Only). They are not medicines and are not intended for use in humans or animals.